The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Willmar Schwabe Award 2006: Antiplasmodial and Antitumor Activity of Artemisinin - From Bench to Bedside
Open accessAbstract
Secondary metabolites from plants serve as defense against herbivores, microbes, viruses, or competing plants. Many medicinal plants have pharmacological activities and may, thus, be a source for novel treatment strategies. During the past 10 years, we have systematically analyzed medicinal plants used in traditional Chinese medicine and focused our interest on Artemisia annua L. (qinhao, sweet wormwood). We found that the active principle of Artemisia annua L., artemisinin, exerts not only antimalarial activity but also profound cytotoxicity against tumor cells. The inhibitory activity of artemisinin and its derivatives towards cancer cells is in the nano- to micromolar range. Candidate genes that may contribute to the sensitivity and resistance of tumor cells to artemisinins were identified by pharmacogenomic and molecular pharmacological approaches. Target validation was performed using cell lines transfected with candidate genes or corresponding knockout cells. The identified genes are from classes with diverse biological functions; for example, regulation of proliferation (BUB3, cyclins, CDC25A), angiogenesis (vascular endothelial growth factor and its receptor, matrix metalloproteinase-9, angiostatin, thrombospondin-1) or apoptosis (BCL-2, BAX, NF-kappaB). Artesunate triggers apoptosis both by p53-dependent and -independent pathways. Antioxidant stress genes (thioredoxin, catalase, gamma-glutamylcysteine synthetase, glutathione S-transferases) as well as the epidermal growth factor receptor confer resistance to artesunate. Cell lines overexpressing genes that confer resistance to established antitumor drugs (MDR1, MRP1, BCRP, dihydrofolate reductase, ribonucleotide reductase) were not cross-resistant to artesunate, indicating that artesunate is not involved in multidrug resistance. The anticancer activity of artesunate has also been shown in human xenograft tumors in mice. First encouraging experience in the clinical treatment of patients suffering from uveal melanoma calls for comprehensive clinical trials with artesunate for cancer treatment in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of the antimalarial drug precursor artemisinic acid in engineered yeast
Ro, D.-K., Paradise, E. M., Ouellet, M., Fisher, K. J., Newman, K. L., Ndungu, J. M., Ho, K. A., Eachus, R. A., Ham, T. S., Kirby, J., et al. (2006) · Nature · doi:10.1038/nature04640 · Cited by 2,805
Engineering a mevalonate pathway in Escherichia coli for production of terpenoids
Martin, V. J. J., Pitera, D. J., Withers, S. T., Newman, J. D., & Keasling, J. D. (2003) · Nature Biotechnology · doi:10.1038/nbt833 · Cited by 1,725
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
The role of angiogenesis in tumor growth.
Folkman, J. (1992) · PubMed · Cited by 1,259
White, N. J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421682 · Cited by 1,248
World Health Organization (2000) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(00)90300-6 · Cited by 1,085
Artemisinins target the SERCA of Plasmodium falciparum
Eckstein-Ludwig, U., Webb, R. J., van Goethem, I. D. A., East, J. M., Lee, A. G., Kimura, M., O'Neill, P. M., Bray, P. G., Ward, S. A., & Krishna, S. (2003) · Nature · doi:10.1038/nature01813 · Cited by 1,027
Sutherland, R., Delia, D., Schneider, C., Newman, R., Kemshead, J., & Greaves, M. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.7.4515 · Cited by 685
The anti-malarial artesunate is also active against cancer
Efferth, T., Dunstan, H., Sauerbrey, A., Miyachi, H., & Chitambar, C. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.4.767 · Cited by 564
Self-citationApoptosis defects and chemotherapy resistance: molecular interaction maps and networks
Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., & Kohn, K. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207515 · Cited by 560
Cited by
Molecular Understanding and Modern Application of Traditional Medicines: Triumphs and Trials
Corson, T. W., & Crews, C. M. (2007) · Cell · doi:10.1016/j.cell.2007.08.021 · Cited by 654
From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy
Efferth, T. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.009 · Cited by 632
Self-citationWhat made sesquiterpene lactones reach cancer clinical trials?
Ghantous, A., Gali-Muhtasib, H., Vuorela, H., Saliba, N. A., & Darwiche, N. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.06.002 · Cited by 615
The Antiviral Activities of Artemisinin and Artesunate
Efferth, T., Romero, M. R., Wolf, D. G., Stamminger, T., Marin, J. J. G., & Marschall, M. (2008) · Clinical Infectious Diseases · doi:10.1086/591195 · Cited by 503
Self-citationRedox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
Wondrak, G. T. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2541 · Cited by 462
Metadata
- Authors
- Efferth, T.
- Venue
- Planta Medica
- Publisher
- Georg Thieme Verlag KG
- Published
- 2007-04
- Volume
- 73
- Issue
- 4
- Pages
- 299-309
- ISSN
- 0032-0943 (ISSN-L)
- 1439-0221
- OpenAlex
- W2095518262
- Cited by
- 269
- References
- 91
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Willmar Schwabe Award 2006: Antiplasmodial and Antitumor Activity of Artemisinin - From Bench to Bedside. https://app.cochat.ai/papers/10.1055/s-2007-967138
- The paper
- Efferth, T. (2007). Willmar Schwabe Award 2006: Antiplasmodial and Antitumor Activity of Artemisinin - From Bench to Bedside. Planta Medica. https://doi.org/10.1055/s-2007-967138
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.